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EASI p-EASI: Predicting disease severity in atopic dermatitis 
patients treated with dupilumab using a combination of serum 
biomarkers
To the Editor,
During the past decade, new more targeted therapies for the treat-
ment of atopic dermatitis (AD) have been developed and are cur-
rently under investigation in clinical trials. However, the comparison 
of results from different clinical studies remains challenging, given 
the substantial variation in clinician-rated outcome measures that 
are currently used, and high inter- and intra-observer dissimilari-
ties.1 An objective and consistent outcome measurement is hence 
needed to successfully compare different treatment options. Serum 
thymus and activation-regulated chemokine (TARC/CCL17) is cur-
rently the best performing objective biomarker for disease sever-
ity in AD.2 Nevertheless, the correlation with disease severity is not 
strong enough to replace clinical outcome measures. Therefore, we 
previously proposed to use a biomarker combination reflecting dif-
ferent underlying pathways and showed that a biomarker signature 
including TARC, soluble interleukin (IL)-2-receptor (sIL-2R), and IL-22 
was a significantly better predictor of disease severity than a single 
biomarker.3 All three biomarkers have been reported to contribute 
to AD pathogenesis. TARC is a T-cell attracting chemokine, involved 
in T-cell recruitment to the skin,3 sIL-2R is a proven marker of T-cell 
activation in vivo,4 and IL-22 induces keratinocyte proliferation and 
inhibits terminal differentiation, thereby promoting epidermal hy-
perplasia and barrier defects.5 Since the model was developed to 
predict Eczema Area and Severity Index (EASI) scores, this objective 
outcome measure was named “the predicted-EASI” (p-EASI). The p-
EASI was developed using data of AD patients treated with topical 
corticosteroids (TCS) and recently validated in cyclosporin A (CsA) 
treated AD patients.6 In the near future, novel immune-modulating 
drugs will transform the management of moderate-to-severe AD. 
Therefore, we aim to validate the p-EASI in patients treated with 
dupilumab, the first human monoclonal antibody-based treatment 
approved for adults with moderate-to-severe AD.7
We included 25 adult patients with moderate-to-severe AD from 
a previously published prospective cohort8 (median age 32, IQR 27-
49, 15 male, Table S1). Patients using oral immunosuppressive drugs 
within two (fast-acting) or four (slow-acting) weeks before baseline 
were excluded. Patients were treated with dupilumab 600 mg at 
initiation followed by 300 mg every other week for 16 weeks. 
Disease severity was assessed by EASI score, and serum was col-
lected before initiation of dupilumab treatment (t0) and after eight 
(t1), twelve (t2), and sixteen (t3) weeks of treatment. Serum TARC, 
sIL-2R, and IL-22 levels were measured via Luminex-based multiplex 
immunoassays using an in-house validated panel of analytes, as pre-
viously described.3,6 Differences between time points were evalu-
ated by Wilcoxon matched-pairs signed-rank test. Patients signed 
Institutional Review Board-approved written consent, adhering to 
the Declaration of Helsinki Principles.
Dupilumab treatment significantly decreased median EASI 
scores from baseline (19.3, IQR 14.2-24.5) through week 8 (me-
dian EASI 5.2, IQR 2.4-8.0, P < .0001), week 12 (3.8, IQR 2.1-6.6, 
P < .0001), and week 16 (median EASI 3.9, IQR 2.4-7.6, P < .0001). 
Median serum TARC and IL-22 levels significantly decreased from 
t0 to t1 and remained stable onwards until t3 (Figure 1). No signifi-
cant change in median serum sIL2r levels was observed during the 
16 weeks of dupilumab treatment.
Serum biomarker levels were used to calculate the p-EASI 
scores at the different time points using the following previously 
published signature3: (−36.12  +  18.49*logTARC  +  0.009*IL-22-
0.009*sIL-2R)*(1-treatment)+(−5.82  +  4.04*logTARC  +  0.003*IL-22-
0.003*sIL-2R)*treatment, in which treatment refers to dupilumab 
treatment, and can be either No = 0, or Yes = 1. The observed and 
predicted-EASI scores showed a high correlation (Spearman correla-
tion r = .67, P < .0001). Median EASI and p-EASI were 19.3 (IQR 
14.2-24.5) and 17.3 (IQR 8.5-20.2), respectively, before treatment, 
5.2 (IQR 2.4-8.0) and 2.8 (IQR 1.6-3.9) after 8 weeks, 3.8 (IQR 2.1-
6.6) and 2.7 (IQR 1.7-4.0) after 12 weeks, and 3.9 (IQR 2.4-7.6) and 
3.1 (IQR 1.9-4.0) after 16 weeks of dupilumab treatment (Figure 2). 
Additionally measured biomarkers (Table S2) were not considered to 
have added value over the current signature, based on correlation 
with disease severity.
The current study demonstrates that the p-EASI corre-
sponds closely to disease severity in AD patients before and after 
8-16 weeks of dupilumab treatment. In comparison with our previ-
ous TCS and CsA treated AD cohorts, the correlation between EASI 
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and p-EASI was slightly lower in dupilumab treated AD patients. This 
may be explained by the sIL-2R levels remaining stable during dupi-
lumab treatment, which was not observed in the other two cohorts. 
By targeting the IL-4Rα, dupilumab specifically inhibits the T helper 
(Th)2-related cytokines IL-4 and IL-13. Although sIL-2R is known to 
reflect T-cell activation and correlate to AD disease severity,4,9 our 
results suggest that it is not influenced by dupilumab treatment. This 
might reflect that this biological only targets T-cell phenotypes di-
rectly involved in AD pathogenesis (Th2 cells). In comparison, CsA 
and, to a lesser amount, TCS have a broad systemic immunosuppres-
sive effect, targeting multiple T-cell phenotypes and related cyto-
kines. As few patients did show a quick drop in sIL-2R, extending 
the current model to a larger patient population including different 
phenotypes of AD might identify subtypes of AD patients in whom 
sIL-2R is an important marker.
The difference between EASI and p-EASI was larger at baseline 
and after 8 weeks of treatment, compared to the later time points. 
The difference at baseline might be explained by an overestimation 
of the EASI score due to a more severe disease at the moment of 
dupilumab initiation compared to the other time points. The EASI 
is a subjective score reflecting the visible skin lesions, while the 
p-EASI objectively reflects the extent and intensity of AD lesions, 
and might be ahead of clinical signs. Since dupilumab is a systemic 
immunomodulating drug, changes in serum biomarkers might occur 
before clinical signs improve. This is supported by our finding that 
the lowest median serum TARC/CCL17 level was observed at week 
8, while lowest median EASI score was observed at week 12. Similar 
results were reported in the previous study of Guttman-Yassky 
et al,10 investigating 54 moderate-to-severe AD patients treated 
with dupilumab for 16 weeks, where the mean percentage change 
F I G U R E  1   Serum TARC, IL-22, and 
sIL-2R levels from 25 AD patients before 
initiation of dupilumab treatment (week 
0) and after 8, 12 and 16 wk of treatment. 
Red lines represent median. Significance 
levels correspond to the following P 


















































F I G U R E  2   Median EASI and predicted-EASI (p-EASI) scores 
in 25 AD patients before initiation of dupilumab treatment (week 
0) and after 8, 12 and 16 wk of treatment. Error bars represent 
interquartile range
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from baseline in serum TARC levels was the highest at week 4. In fu-
ture, the change in p-EASI during the first weeks of treatment might 
potentially be used to predict response to dupilumab in AD patients.
The current study demonstrates that a biomarker signature 
(p-EASI) consisting of serum biomarkers TARC, IL-22, and sIL-2R 
adequately predicts disease severity in AD patients treated with 
dupilumab, in addition to previously published cohorts of TCS and 
CsA treated AD patients.3,6 The use of p-EASI measured via a stan-
dardized assay will help to improve comparability of study outcomes 
in future clinical trials on new more targeted therapies for AD, but 
may also be helpful as an objective measure for treatment effects in 
daily practice.
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